The New Haven, Conn., biopharmaceutical company said Monday that taldefgrobep had shown clinically meaningful improvements in motor function in spinal muscular atrophy patients, but the treatment arm ...

Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.

Taldefgrobep alfa as an add-on therapy significantly improved motor function in pivotal Phase 3 trial, but racial differences ...